BeOne Medicines (formerly BeiGene) is a global oncology company developing innovative and affordable cancer treatments. Founded in 2010, it operates across more than 45 countries and six continents, advancing a broad portfolio of medicines aimed at improving treatment access and outcomes for cancer patients worldwide. The company is publicly traded on the NASDAQ, the Hong Kong Stock Exchange and the STAR Market, and maintains an office in Herzliya, Israel.